Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 425

1.

Spindle poisons and cell fate: a tale of two pathways.

Matson DR, Stukenberg PT.

Mol Interv. 2011 Apr;11(2):141-50. doi: 10.1124/mi.11.2.12. Review.

2.

CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S.

Mol Interv. 2011 Apr;11(2):133-40. doi: 10.1124/mi.11.2.11. Review.

3.

Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.

Kelly EJ, Nakano M, Rohatgi P, Yarov-Yarovoy V, Rettie AE.

Mol Interv. 2011 Apr;11(2):124-32. doi: 10.1124/mi.11.2.10. Review.

4.

New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.

Choi J, Kermode JC.

Mol Interv. 2011 Apr;11(2):111-23. doi: 10.1124/mi.11.2.9. Review.

PMID:
21540471
5.

The secrets of a successful clinical trial: compliance, compliance, and compliance.

Czobor P, Skolnick P.

Mol Interv. 2011 Apr;11(2):107-10. doi: 10.1124/mi.11.2.8. No abstract available.

6.

Asthma therapeutics: recent strides, new hurdles.

Mullane K.

Mol Interv. 2011 Apr;11(2):103-6. doi: 10.1124/mi.11.2.7. No abstract available.

PMID:
21540469
7.

Mind the dbGAP: the application of data mining to identify biological mechanisms.

Wooten EC, Huggins GS.

Mol Interv. 2011 Apr;11(2):95-102. doi: 10.1124/mi.11.2.6. No abstract available.

8.

Microvesicles: intercellular vectors of biological messages.

Tual-Chalot S, Leonetti D, Andriantsitohaina R, Martínez MC.

Mol Interv. 2011 Apr;11(2):88-94. doi: 10.1124/mi.11.2.5. No abstract available.

PMID:
21540467
9.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466
10.

Lady Mildmay's modern medical cures.

Anderson RJ.

Mol Interv. 2011 Apr;11(2):72-8. doi: 10.1124/mi.11.2.2. No abstract available.

PMID:
21540465
11.

Florence Nightingale: the biostatistician.

Anderson RJ.

Mol Interv. 2011 Apr;11(2):63-71. doi: 10.1124/mi.11.2.1. No abstract available.

PMID:
21540464
12.

Molecular interventions (2001-2011): an experiment completed.

Lazo JS.

Mol Interv. 2011 Apr;11(2):62. doi: 10.1124/mi.11.2.0. No abstract available.

PMID:
21540463
13.

Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Seely KA, Prather PL, James LP, Moran JH.

Mol Interv. 2011 Feb;11(1):36-51. doi: 10.1124/mi.11.1.6. Review.

14.

NOX isoforms and reactive oxygen species in vascular health.

Touyz RM, Briones AM, Sedeek M, Burger D, Montezano AC.

Mol Interv. 2011 Feb;11(1):27-35. doi: 10.1124/mi.11.1.5. Review.

PMID:
21441119
15.

STAT3 signaling: anticancer strategies and challenges.

Johnston PA, Grandis JR.

Mol Interv. 2011 Feb;11(1):18-26. doi: 10.1124/mi.11.1.4. Review.

16.

Traveling backward: de-differentiation to stemness.

Hoffmann A, Tsonis PA.

Mol Interv. 2011 Feb;11(1):15-7. doi: 10.1124/mi.11.1.3. No abstract available.

PMID:
21441117
17.

"Be open and experiment!".

Rutledge C.

Mol Interv. 2011 Feb;11(1):10-4. doi: 10.1124/mi.11.1.2. No abstract available.

PMID:
21441116
18.

The courage of one's convictions: the due diligence of Frances Oldham Kelsey at the FDA.

Scheindlin S.

Mol Interv. 2011 Feb;11(1):3-9. doi: 10.1124/mi.11.1.1. No abstract available.

PMID:
21441115
19.

The promise of epigenetics in personalized medicine.

Weber WW.

Mol Interv. 2010 Dec;10(6):363-70. doi: 10.1124/mi.10.6.5. Review.

PMID:
21263162
20.

Antioxidants in hypertension and cardiovascular disease.

Schiffrin EL.

Mol Interv. 2010 Dec;10(6):354-62. doi: 10.1124/mi.10.6.4. Review.

PMID:
21263161

Supplemental Content

Loading ...
Support Center